chevron_leftBack
As of 24 April 2025, MedinCell S.A. has a market cap of $553.07M USD, ranking #11374 globally and #182 in France. It ranks #1108 in the Healthcare sector, and #289 in the Biotechnology industry.
Key Stats
Market Cap
$553.07MUSD
486.02M EUR
Enterprise Value
$587.59MUSD
516.36M EUR
Revenue (TTM)
$15.02MUSD
13.2M EUR
EBITDA (TTM)
-$21.4MUSD
-18.81M EUR
Net Income (TTM)
-$35.79MUSD
-31.45M EUR
EBITDA Margin
-143%
Profit Margin
-238%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Christophe Douat
open_in_new
Employees
134
Founded
2003
Website
medincell.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1.5% | 5.9% | -1.3% | -7.6% | -5.9% | 28% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
MEDCL
Medincell SA
ISIN: FR0004065605
Shares Out.:
Shares Outstanding:
33.069M1
Shares Float:
24.156M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
14.92 EUR | |
|
0ACH
Medincell SA
ISIN: FR0004065605
|
14.11 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About MedinCell S.A.
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
